Can a new drug shrink Hard-to-Treat lymphoma tumors?
NCT ID NCT06074107
First seen Aug 18, 2026 · Last updated Aug 18, 2026
Summary
This phase II trial is testing an experimental drug called BEBT-908 in adults with diffuse large B-cell lymphoma that has come back or not responded to at least two prior treatments. The study aims to see how well BEBT-908 shrinks tumors and controls the disease, as well as how safe it is. Participants receive the drug through an IV on several days per cycle, for up to six cycles. The trial also looks at how long any response lasts and whether certain biomarkers predict who benefits.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BEBT-908 (also known as CUDC-908), an experimental drug given by intravenous infusion.
- What this could lead to
- If successful, this could provide a new treatment option for patients with diffuse large B-cell lymphoma who have not responded to prior therapies, potentially improving tumor control and survival.
- What could go wrong
- This is a phase II trial, so the drug's effectiveness and safety are not yet proven. It may not work for all patients, and there could be side effects. The results will need confirmation in larger trials.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, 100021, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New hope for hard-to-treat lymphoma: experimental drug combo enters phase 3 trial
- New combo offers hope for aggressive lymphoma in diverse patients
- Experimental cocktail aims to tackle tough lymphoma
- Double punch: CAR-T cells followed by antibodies may boost lymphoma remission
- New pill shows promise for Hard-to-Treat lymphoma
- New hope for tough lymphoma: targeted drug shows promise